细菌溶解产物胶囊联合沙美特罗替卡松治疗对哮喘患者血清炎症介质的影响

Effects of Bacteriolysis Product Capsule Combined with Salmeterol and Roticasone on Serum Inflammatory Mediators in Asthma Patients

目的探讨细菌溶解产物胶囊联合沙美特罗替卡松治疗对哮喘患者血清炎症介质的影响。方法选取中国人民解放军北部战区总医院呼吸科2017年5月至2018年5月收治的88例哮喘患者作为研究对象,将其随机分为观察组和对照组,各44例。对照组给予沙美特罗替松治疗,观察组在对照组基础上采用细菌溶解产物胶囊治疗。比较两组患者临床疗效、治疗前后肺功能相关指标[呼气峰值流速(PEF)、用力肺活量(FVC)、第一秒钟用力呼气容积/用力肺活量(FEV1/FVC)],以及治疗前后炎症介质[肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)]水平和淋巴细胞亚群水平变化情况。结果观察组治疗有效率93.18%高于对照组的75.00%,差异有统计学意义(P<0.05);观察组治疗后PEF(7.67±1.74)L/s、FVC(3.15±0.09)L、FEV1/FVC(92.06±4.23)%均高于对照组PEF(7.13±1.49)L/s、FVC(2.86±0.16)L、FEV1/FVC(82.64±4.45)%,血清TNF-α(449.86±46.12)ng/L、IL-8(62.58±23.75)ng/L水平均明显低于对照组TNF-α(796.47±69.25)ng/L、IL-8(76.48±24.23)ng/L,差异有统计学意义(P<0.05);血清CD4+、CD8+、CD4+/CD8+水平分别为(38.37±3.68)%、(28.87±2.56)%、1.58±0.42,均高于对照组的(35.12±3.42)%、(26.07±2.48)%、1.37±0.39,差异有统计学意义(P<0.05)。结论细菌溶解产物胶囊联合沙美特罗替卡松治疗可有效改善哮喘患者临床症状,提高肺功能,降低血清炎症介质水平,且安全性较高。

Objective To explore the effects of bacterial lysate capsules combined with salmeterol and fluticasone on serum inflammatory mediators in patients with asthma. Methods A total of 88 asthmatic patients admitted to the Respiratory Department of the General Hospital of the Northern War Zone of the Chinese People’s Liberation Army from May 2017 to May 2018 were randomly divided into observation group and control group, with 44 cases in each group. The control group was treated with salmeterol and the observation group was treated with bacterial lysate capsules on the basis of the control group. The clinical efficacy, lung function related indexes [peak expiratory flow rate(PEF), forced vital capacity(FVC), forced expiratory volume and forced vital capacity in the first second(FEV1/FVC)], inflammatory mediators [tumor necrosis factor-alpha(TNF-alpha), interleukin-8(IL-8)] levels and changes in lymphocyte subsets before and after treatment were compared between the 2 groups were compared. Results The effective rate of the observation group was 93.18% higher than that of the control group of 75.00%(P<0.05). After treatment, the PEF(7.67±1.74) L/s, FVC(3.15±0.09) L, FEV1/FVC(92.06±4.23)% of the observation group were higher than those of the control group(7.13±1.49) L/s, FVC(2.86±0.16) L, FEV1/FVC(82.64±4.45)% and the levels of serum TNF-alpha(449.86±46.12) ng/L and IL-8(62.58±23.75) ng/L were significantly lower than those of TNF-α(796.47±69.25) ng/L and IL-8(76.48±24.23) ng/L in the control group,(P<0.05);the levels of serum CD4+, CD8+, and CD4+/CD8+ were(38.37±3.68)%,(28.87±2.56)% and(1.58±0.42), respectively, which were higher than those of the control group(35.12±3.42)%,(26.07±2.48)%,(1.37±0.39),(P<0.05). Conclusion Bacteriolysis product capsule combined with salmeterol and fluticasone can effectively improve the clinical symptoms of asthma patients, improve lung function, reduce the level of serum inflammatory mediators, and has high safety.